AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Miracle Mile Advisors LLC

Miracle Mile Advisors LLC grew its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 445.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,986 shares of the company's stock after purchasing an additional 32,659 shares during the quarter. Miracle Mile Advisors LLC's holdings in AstraZeneca were worth $2,620,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Sivia Capital Partners LLC raised its holdings in AstraZeneca by 3.2% during the fourth quarter. Sivia Capital Partners LLC now owns 7,390 shares of the company's stock worth $484,000 after purchasing an additional 226 shares in the last quarter. Moody National Bank Trust Division raised its stake in AstraZeneca by 20.0% during the 4th quarter. Moody National Bank Trust Division now owns 4,556 shares of the company's stock worth $299,000 after acquiring an additional 758 shares in the last quarter. Trust Co. of Toledo NA OH lifted its position in AstraZeneca by 4.6% in the fourth quarter. Trust Co. of Toledo NA OH now owns 7,651 shares of the company's stock valued at $501,000 after acquiring an additional 337 shares during the last quarter. West Oak Capital LLC boosted its stake in AstraZeneca by 1,318.9% in the fourth quarter. West Oak Capital LLC now owns 2,483 shares of the company's stock valued at $163,000 after acquiring an additional 2,308 shares in the last quarter. Finally, A. D. Beadell Investment Counsel Inc. purchased a new position in shares of AstraZeneca during the fourth quarter worth about $876,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently commented on AZN shares. UBS Group upgraded shares of AstraZeneca from a "sell" rating to a "neutral" rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a "sell" rating to a "hold" rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $89.75.

AstraZeneca Price Performance

Shares of NASDAQ AZN traded down $0.36 during trading on Tuesday, reaching $65.37. The company had a trading volume of 6,246,268 shares, compared to its average volume of 4,968,281. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The stock has a 50-day moving average price of $65.98 and a two-hundred day moving average price of $74.69. The stock has a market capitalization of $202.69 billion, a PE ratio of 31.28, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the firm posted $0.87 earnings per share. The company's quarterly revenue was up 18.0% compared to the same quarter last year. As a group, sell-side analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.